Aclaris Therapeutics announced positive full results from its Phase 1a trial of ATI-052, a novel anti-TSLP/IL-4Rα bispecific antibody showing strong potency, safety, and a long half-life enabling up to three-month dosing. The company is progressing ATI-052 into Phase 1b trials for asthma and atopic dermatitis, with Phase 2b planned for late 2026. Additionally, Aclaris selected lichen planus as the lead indication for ATI-2138, an oral ITK/JAK3 inhibitor targeting pathogenic T cells, with a Phase 2b basket study expected to start in the second half of 2026. These developments highlight Aclaris' focus on innovative treatments for immuno-inflammatory diseases with significant unmet needs.
National Beverage faces stagnant growth as LaCroix volumes have declined for four straight years, reducing brand excitement. The stock trades at reasonable multiples reflecting muted growth and no clear catalysts for upside. Despite stable gross marg...
Arthur Hayes reversed his crypto strategy by purchasing over $3.7 million worth of Ethereum after selling 6,000 ETH at a loss of about $606,000 just weeks prior. This move follows his pattern of bold crypto trades and quick exits, which have drawn cr...
A bitcoin wallet that had been inactive since 2017 moved its entire holding of 5,908 BTC, now worth about $383 million, to a new, unidentified address. The coins were originally bought near bitcoin's 2017 peak at around $16,000 each and have gained r...
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
The US will impose a 25% tariff on most imports from Brazil starting July 22, following a yearlong investigation into alleged unfair trade practices by Brazil. The tariffs target issues such as Brazil's demands on US tech firms to remove political co...
